NASDAQ NMS - GLOBAL MARKET · MCRB
+13.24% · +$0.3600 · Vol Not reported
Pre-market · updated 04:00:06 ET
Seres Therapeutics Inc

Seres Therapeutics Inc

Biotechnology
$3.08
Card
Relationship Map

Follow $MCRB

One email when a member of Congress discloses a trade in it, with the official filing receipt linked.

Free. No account. Unsubscribe in one click.

Follow $MCRB by email

Veridion Score

BETAMEDIUM CONF · 6 of 6 factors measuredMethodology
MCRB
Seres Therapeutics Inc
Wed Oct 7 · last completed session · Pre-market · regular session opens 9:30 ET
Middle range

Highest qualified requires a score of at least 75 and high confidence, including full factor coverage. Upper range can hold a higher score with lower confidence.

Composite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.

48/ 100
Veridion Score
Middle range · MEDIUM confidence · 6 of 6 factors measured
Sovereign · $25/mo
See why this score moved.
  • · Factor breakdown with raw signals
  • · Day-over-day delta + driver
  • · Factor coverage readout
  • · Valuation · hype · market flow
  • · Pro Chart event markers
  • · Score history + alerts
Start Sovereign · $25/mo →
Cancel anytime · or Reserve · $79/mo
Confidence: MEDIUM · 6 of 6 factors measured · Wed Oct 7 · last completed session · Pre-market · regular session opens 9:30 ET
Share on X →
Veridion Score History · 90D
Loading score history
AI Analysis
Sovereign

Why is MCRB moving today?

Sovereign unlock connects news, insider activity, analyst moves, and live price action.
Loading MCRB catalysts
About Seres Therapeutics Inc
PHARMACEUTICAL PREPARATIONS
Listed since
2015
Employees
66
Country
US

Seres Therapeutics Inc is a clinical-stage biotechnology company focused on the development of live biotherapeutic candidates. Its pipeline includes candidates such as SER-155 and SER-603, aimed at preventing and treating bacterial infections, antimicrobial resistance, and gastrointestinal immune diseases. The company operates as a single reportable segment, mainly developing microbiome-based therapies targeting bacterial infections, antimicrobial resistance, and gastrointestinal immune diseases.

Company website →
Key statistics

Reported fields plus Veridion-computed history. Unsourced tiles are omitted.

Open
$2.72
Last session
Day high
$2.72
Last session
Day low
$2.72
Last session
Previous close
$2.72
52W high
$28.63
-89.24% from high
52W low
$2.72
1% of range
Market cap
$27.3M
P/E
4.85×
EPS
$-2.3343
Beta
0.67
Shares out
10M
Avg volume
63.8K
VWAP
$2.72
Last session
Price history computed in-house
1W
+5.12%
1M
-44.60%
3M
-49.59%
1Y
-84.32%
YTD
-79.30%
SMA 50 $4.46 · below
SMA 200 $8.21 · below
52W position 1%

MCRB overview

Veridion Score
48
Registered · 2026-10-07
6 of 6 factors measured
Latest receipt rows
0
No recent disclosure on file.
13F holders
None on file

Related filings and maps

Relationship mapTrace receipt-backed holders and filings around MCRB.Congress trackerSearch the public STOCK Act disclosure ledger.MethodologyReview score inputs, coverage rules, and limitations.
Loading financial statements
Loading MCRB Form 4 filings
Public disclosures

Congress activity in MCRB

Congress trackerOpen ticker disclosure ledger →

No receipt-qualified filings found.

Federal contracts

MCRB contract awards, year to date.

Public federal awards linked to this ticker.

Not disclosed
Refresh interval: 12hSource: Federal contract awards
No federal contracts on file for MCRB in this window.
Lobbying spend

MCRB lobbying filings, year to date.

Registered lobbying filings matched to Seres Therapeutics Inc.

Not disclosed
Refresh interval: 12hSource: LDA disclosure filings
No lobbying filings on file for MCRB in this window.
Loading news for MCRB
Analyst ratings
Sovereign unlock shows live analyst consensus for MCRB.
Options
Options data is temporarily unavailable. Changing your plan will not restore the upstream feed.
Weekly Veridion brief

Rating changes, public disclosure activity, methodology notes, and product updates. One email per week. No advertising list resale.